NasdaqGS - Nasdaq Real Time Price USD
Amgen Inc. (AMGN)
296.88
+1.78
+(0.60%)
At close: August 1 at 4:00:00 PM EDT
297.55
+0.67
+(0.23%)
After hours: August 1 at 7:31:32 PM EDT
Loading Chart for AMGN
- Previous Close
295.10 - Open
297.06 - Bid 281.15 x 100
- Ask 311.20 x 100
- Day's Range
292.59 - 298.52 - 52 Week Range
253.30 - 339.17 - Volume
2,410,026 - Avg. Volume
2,574,654 - Market Cap (intraday)
159.634B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
27.04 - EPS (TTM)
10.98 - Earnings Date Aug 5, 2025
- Forward Dividend & Yield 9.52 (3.21%)
- Ex-Dividend Date May 16, 2025
- 1y Target Est
313.48
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com28,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AMGN
View More
Related Videos: AMGN
Performance Overview: AMGN
Trailing total returns as of 8/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
AMGN
15.84%
S&P 500 (^GSPC)
6.06%
1-Year Return
AMGN
8.66%
S&P 500 (^GSPC)
14.53%
3-Year Return
AMGN
32.94%
S&P 500 (^GSPC)
51.46%
5-Year Return
AMGN
41.78%
S&P 500 (^GSPC)
90.70%
Compare To: AMGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMGN
View MoreValuation Measures
As of 8/1/2025
Market Cap
159.63B
Enterprise Value
208.21B
Trailing P/E
27.06
Forward P/E
14.18
PEG Ratio (5yr expected)
0.99
Price/Sales (ttm)
4.72
Price/Book (mrq)
25.72
Enterprise Value/Revenue
6.10
Enterprise Value/EBITDA
13.62
Financial Highlights
Profitability and Income Statement
Profit Margin
17.39%
Return on Assets (ttm)
7.04%
Return on Equity (ttm)
105.67%
Revenue (ttm)
34.13B
Net Income Avi to Common (ttm)
5.93B
Diluted EPS (ttm)
10.98
Balance Sheet and Cash Flow
Total Cash (mrq)
8.81B
Total Debt/Equity (mrq)
924.46%
Levered Free Cash Flow (ttm)
13.09B
Research Analysis: AMGN
View MoreResearch Reports: AMGN
View MoreAmgen: We Still See Obesity Market Niche for Maritide Despite Tolerability Struggles
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetAmgen: We Still See Obesity Market Niche for Maritide Despite Tolerability Struggles
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetAmgen: We Still See Obesity Market Niche for Maritide Despite Tolerability Struggles
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetAmgen Earnings: On Track to Meet 2025 Guidance Following Broad-Based Growth in First Quarter
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice Target